Business Wire - The global leader in news distribution
Updated: 4 min 51 sec ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AI?src=hash" target="_blank"gt;#AIlt;/agt;--ReviveMed Inc, an AI-driven drug discovery platform, today announced that CEO Dr. Leila Pirhaji has been selected as a TED Fellow, joining a class of 20 change-makers from around the world to deliver a talk on the TED stage this April in Vancouver. Dr. Pirhaji was selected in recognition of her scientific and entrepreneurial work at the intersection of artificial intelligence and biology. “I am thrilled to share how we can use technology and artificial intelli
Triumvira Announces Build out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development
AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira appoints Andreas Bader as Senior Vice President of Research & Development and Joshua Carle as Vice President of Business Development.
STEMCELL Technologies Launches mTeSR™ Plus, a Next-Generation Culture System for Human ES and iPS Cell Maintenance
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies has released mTeSR™ Plus, an enhanced version of mTeSR™1, the most widely published feeder-free human pluripotent stem cell (hPSC) maintenance medium. The new medium has undergone successful beta testing with several members of the Stem Cell COREdinates group and has completed rigorous in-house validation testing. Designed to promote a more consistent cell culture environment through sustained medium pH and stabilized component
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerate
CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune confirm Canadian patent grant which covers PredictImmune’s intellectual property relating to methods for predicting autoimmune disease
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) to evaluate the efficacy, safety and tolerability at four weeks in
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Ag-West Bio series of short video vignettes offer a window into the labs and lives of five Saskatchewan scientists.
Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
LAUSANNE, SWITZERLAND, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anokion (“Anokion” or the “Company”), a leading immune tolerance company advancing novel, antigen-specific treatments for autoimmune disease, today announced that Simon Cooper, MBBS., has been appointed to the newly created position of chief medical officer. Dr. Cooper will lead Anokion’s team that is advancing the company’s development pipeline into clinical testing, with the first trial expected to commence by late 2019. Dr. Cooper w
Newron Pharmaceuticals: Commercialization Partner Zambon Together with Valeo Pharma Announce the Approval of Onstryv® (safinamide) for Parkinson’s Disease in Canada
MILAN--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24NWRN&src=ctag" target="_blank"gt;$NWRNlt;/agt; lt;a href="https://twitter.com/hashtag/Parkinsons?src=hash" target="_blank"gt;#Parkinsonslt;/agt;--Newron Pharmaceuticals' partner Zambon, together with Valeo Pharma, announce the approval of Onstryv® (safinamide) for Parkinson’s disease in Canada.
COBOURG, Ontario--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/N1002018?src=hash" target="_blank"gt;#N1002018lt;/agt;--Northumberland CFDC today announced that Argentum Electronics is the winner of its 2018 $250,000 N100 Evolution technology startup competition. The multi-stage competitive gauntlet began in July 2018 at Venture13 in Cobourg, with a total of 44 startups competing at the outset. Argentum Electronics has designed a product line of Power-over-Ethernet (PoE) technologies and smart power management solutions, working within an ecosystem of innovative architects, bui
SASKATOON, Saskatchewan--(BUSINESS WIRE)--A new Diverse Field Crops Cluster has received over $13 million in federal funding.
MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/amorchem?src=hash" target="_blank"gt;#amorchemlt;/agt;--Back by popular demand, AmorChem is hosting its fifth KNOCK OUT Event during the 1st edition of the EFFERVERSCENCE conference, April 24th, 2019 in Montreal. Researchers selected to participate in the Dragons’ Den inspired AmorChem KNOCK OUTTM Event will fight it out in the ring against our panel of “heavyweights” eager to defend their title. If you are an academic life science researcher with an appetite to KNOCK OUT the competition, if you have innovative science wit
BRESSO, Italy--(BUSINESS WIRE)--Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to commercializing innovative prescription products in Canada, today announce the approval of Onstryv® (safinamide) for the treatment of Parkinson’s Disease in Canada. Under the terms of the agreement with Zambon, Valeo Pharma is responsible for all regulatory, quality,
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24QGEN&src=ctag" target="_blank"gt;$QGENlt;/agt;--QIAGEN’s QuantiFERON®-TB Gold Plus gains approval in Canada
Peer-Reviewed Paper Featuring Titan Medical’s Single-Port Robotic Surgical Platform in General Surgery Published in Surgical Endoscopy
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that a peer-reviewed multi-faculty paper featuring Titan’s single-port platform has been published in the January 2019 issue of Surgical Endoscopy. The paper highlights the feasibility, safety and ease of use of Titan’s single-port
TORONTO--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;--FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "LOVE". FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. Antho
MONTRÉAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/amorchem?src=hash" target="_blank"gt;#amorchemlt;/agt;--AmorChem II is proud to announce the closing of its first financing of a university project. The venture capital fund has reached an agreement with Univalor, Dr Éric Lécuyer of the Montreal Clinical Research Institute (“IRCM”), Dr. Mathieu Blanchette and Dr. Jérôme Waldispühl of McGill University to collaborate on a project focusing on short sequences of RNA that direct intracellular traffic (“RNA Zipcodes”). “Recent years have seen a resurgence in the development of
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today advising that it has reported an anticipated shortage of certain doses of ESTRACE® on the Drug Shortages Canada website in relation to supply issues arising from the Company’s contract manufacturer. The Company had previously been notified by its contract manufacturer of a partial manufacturing license suspension at the facility where ESTRACE® is being produced as a result of an audit by
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology and Knight Therapeutics have entered into an exclusive license agreement to commercialize NERLYNX® (neratinib) in Canada.